Combination Therapy Using Microwave Ablation and D-Mannose-chelated Iron Oxide Nanoparticles Inhibits Hepatocellular Carcinoma Progression.

Rui Cui,Luo Wang,Dongyun Zhang,Kun Zhang,Jianping Dou,Linan Dong,Yixuan Zhang,Jiapeng Wu,Longfei Tan,Jie Yu,Ping Liang
DOI: https://doi.org/10.1016/j.apsb.2022.05.026
IF: 14.903
2022-01-01
Acta Pharmaceutica Sinica B
Abstract:Despite being a common therapy for hepatocellular carcinoma (HCC), insufficient thermal ablation can leave behind tumor residues that can cause recurrence. This is believed to augment M2 inflammatory macrophages that usually play a pro-tumorigenic role. To address this problem, we designed d-mannose-chelated iron oxide nanoparticles (man-IONPs) to polarize M2-like macrophages into the antitumor M1 phenotype. In vitro and in vivo experiments demonstrated that man-IONPs specifically targeted M2-like macrophages and accumulated in peri-ablation zones after macrophage infiltration was augmented under insufficient microwave ablation (MWA). The nanoparticles simultaneously induced polarization of pro-tumorigenic M2 macrophages into antitumor M1 phenotypes, enabling the transformation of the immunosuppressive microenvironment into an immunoactivating one. Post-MWA macrophage polarization exerted robust inhibitory effects on HCC progression in a well-established orthotopic liver cancer mouse model. Thus, combining thermal ablation with man-IONPs can salvage residual tumors after insufficient MWA. These results have strong potential for clinical translation.
What problem does this paper attempt to address?